Literature DB >> 23401410

Five novel mutations of GALNS in Korean patients with mucopolysaccharidosis IVA.

Hyung-Doo Park1, Ah-Ra Ko, Chang-Seok Ki, Soo-Youn Lee, Jong-Won Kim, Sung Yoon Cho, Se Hwa Kim, Sung Won Park, Young Bae Sohn, Dong-Kyu Jin.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA; OMIM #253000) is caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), a lysosomal enzyme involved in the catabolism of keratan and chondroitin sulfate. In this study, we examined biochemical and genetic data from 6 Korean patients presenting with classic MPS IVA by measuring GALNS activity in peripheral blood leukocytes and skin fibroblasts. We initially identified Korean patients with MPS IVA by clinical, biochemical, and genetic analyses. We performed PCR-direct sequencing to identify molecular defects of the GALNS gene in patients and assessed the mutational statuses of family members as well as 50 healthy unrelated subjects. In silico analyses were performed to check for novel mutations. The mean age of the six female patients was 8.0 ± 5.2 years (range: 2-17 years), and were all found to have severe reductions of GALNS enzyme. A total of 12 mutant alleles were identified, corresponding to 7 different mutations. Five novel mutations were c.218A>G (p.Y73C), c.451C>A (p.P151T), c.725C>G (p.S242C), c.752G>A (p.R251Q), and c.1000C>T (p.Q334X). Two other mutations were c.1156C>T (p.R386C) and c.1243-1G>A. Two mutations, c.451C>A and c.1000C>T, accounted for 58% of all mutations in this sample.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23401410     DOI: 10.1002/ajmg.a.35298

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  4 in total

Review 1.  An overview of Korean patients with mucopolysaccharidosis and collaboration through the Asia Pacific MPS Network.

Authors:  Sung Yoon Cho; Young Bae Sohn; Dong-Kyu Jin
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.

Authors:  A Morrone; K L Tylee; M Al-Sayed; A C Brusius-Facchin; A Caciotti; H J Church; M J Coll; K Davidson; M J Fietz; L Gort; M Hegde; F Kubaski; L Lacerda; F Laranjeira; S Leistner-Segal; S Mooney; S Pajares; L Pollard; I Ribeiro; R Y Wang; N Miller
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

3.  Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA.

Authors:  Seung Hoon Lee; Hwa Young Kim; Tae-Joon Cho; Hyoungmin Kim; Jung Min Ko
Journal:  Mol Genet Metab Rep       Date:  2022-04-15

4.  An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors.

Authors:  Hassan Brim; Mones S Abu-Asab; Mehdi Nouraie; Jose Salazar; Jim Deleo; Hadi Razjouyan; Pooneh Mokarram; Alejandro A Schaffer; Fakhraddin Naghibhossaini; Hassan Ashktorab
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.